Former FDA Deputy Commissioner Gottlieb Now Pushing Big Pharma Drugs

Email this article to a friend

Printable Version

Articles Related to This Article: • FDA drug safety bill passes in the U.S. Senate; health freedom advocates outraged at betrayal of American consumers • Americans betrayed by Democratic senators with surprise amendment that protects Big Pharma monopoly • India's Waterways A Toxic Stew of Pharmaceutical Chemicals Dumped from Big Pharma Factories Sign the Health Revolution Petition Join the call for genuine health freedom in America. End FDA tyranny and Big Pharma corruption. Watch the video and sign the petition here.

(NaturalNews) Scott Gottlieb, the former FDA Deputy Commissioner for medical and scientific affairs, is now actively involved in the marketing of Eli Lilly's drug raloxifene, marketed as Evista.

Due to his Wall Street connections with the pharmaceutical industry, Gottlieb frequently had to recuse himself from discussions that were part of his FDA duties. He gained notoriety for calling the early termination of a multiple sclerosis drug study "an overreaction," even though three participants had died, and was highly critical of the groundbreaking Women's Health Initiative study, which found that hormone replacement therapy posed more risks than benefits to women's health.

In 2005, Eli Lilly was convicted of illegally marketing osteoporosis drug Evista for off-label treatment and prevention of heart disease and cancer. According to Justice Department documents, Eli Lilly decided to market the drug off-label when early sales of the drug for osteoporosis alone proved disappointing.

Now Gottlieb has accused the government of unfairly penalizing Eli Lilly, with potentially "fatal" consequences for patients, because new studies have led the FDA to approve Evista for use in preventing breast cancer. Eli Lilly's illegal, off-label marketing was, in fact, a "public service," Gottlieb says.

But like the related treatment of hormone replacement therapy, Evista has come under fire for posing unacceptable risks to women's health. Like hormone replacement therapy, Evista increases the risk of fatal blood clots, including "venous thromboembolism and death from stroke," according to the product's warning label. In tests on mice and rats, doses of Evista lower than those regularly prescribed were observed to induce ovarian cancer.

Evista acts on the body's estrogen receptors to selectively inhibit and increase estrogen-like activity in various parts of the body.

According to the Women's Health Initiative study, hormone replacement therapy leads to a 26 percent higher risk of breast cancer, a 29 percent higher risk of heart attack, a 41 percent higher risk of stroke and a 100 percent higher risk of blood clots.

Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • FDA drug safety bill passes in the U.S. Senate; health freedom advocates outraged at betrayal of American consumers • Americans betrayed by Democratic senators with surprise amendment that protects Big Pharma monopoly • India's Waterways A Toxic Stew of Pharmaceutical Chemicals Dumped from Big Pharma Factories	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/023684_Big_Pharma_Eli_Lilly_health.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/023684_Big_Pharma_Eli_Lilly_health.html">Former FDA Deputy Commissioner Gottlieb Now Pushing Big Pharma Drugs</a>